Kamada (NASDAQ:KMDA) Stock Passes Below Two Hundred Day Moving Average of $4.53

Kamada Ltd. (NASDAQ:KMDA – Get Rating)’s share price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $4.53 and traded as low as $4.23. Kamada shares last traded at $4.28, with a volume of 30,316 shares traded.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on shares of Kamada in a report on Saturday, December 31st. They set a “buy” rating for the company.

Kamada Trading Down 1.2 %

The stock has a market cap of $191.83 million, a P/E ratio of -18.61 and a beta of 1.00. The business’s 50 day simple moving average is $4.48 and its 200 day simple moving average is $4.53. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.95 and a quick ratio of 0.90.

Institutional Trading of Kamada

A number of hedge funds and other institutional investors have recently modified their holdings of KMDA. Millennium Management LLC acquired a new stake in Kamada during the 4th quarter worth $314,000. Norges Bank bought a new stake in Kamada in the 4th quarter valued at $131,000. Susquehanna International Group LLP bought a new stake in Kamada in the 4th quarter valued at $41,000. Wells Fargo & Company MN increased its stake in Kamada by 4.5% in the 4th quarter. Wells Fargo & Company MN now owns 513,876 shares of the biotechnology company’s stock valued at $2,000,000 after buying an additional 22,013 shares during the last quarter. Finally, Phoenix Holdings Ltd. increased its stake in Kamada by 2.2% in the 4th quarter. Phoenix Holdings Ltd. now owns 2,105,523 shares of the biotechnology company’s stock valued at $8,443,000 after buying an additional 45,612 shares during the last quarter. Institutional investors and hedge funds own 15.29% of the company’s stock.

About Kamada

(Get Rating)

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties.